BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter AnalysisPalma Fedele, Gennaro Gadaleta‐Caldarola, Raffaele Ardito et al.|Journal of Clinical Medicine|2025Cited by 4
Impact of Chemotherapy Dose Intensity on Pathological Complete Response in Pembrolizumab-Treated Early Triple-Negative Breast Cancer: A Real-World Multicenter AnalysisPalma Fedele, Gennaro Gadaleta‐Caldarola, Luigia Stefania Stucci et al.|Cancers|2025Cited by 3
BRCA1/2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter AnalysisPalma Fedele, Gennaro Gadaleta‐Caldarola, Alessandro Rizzo et al.|Preprints.org|2025Cited by 1
Real-world Predictors of Early Mortality and Treatment Discontinuation in HCC Patients Treated with Atezolizumab–BevacizumabPalma Fedele, Gennaro Gadaleta-Caldarola, Matteo Landriscina et al.|Journal of Gastrointestinal Cancer|2026Cited by 0